Capital Flow Monitor · Sponsors · CIK 2087034
OrbiMed Asia Partners VI, L.P.
601 LEXINGTON AVENUE, NEW YORK, NY, 10022 · 212-739-6400
Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. CAYMAN ISLANDS true 2025
Fit score
—
Offering
$850.0M
Sold
$534.0M
% sold
62.8%
Investors
45
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-05-28 | D/A ·current | 506(b) | $850.0M | $534.0M | 62.8% | 45 | EDGAR ↗ |
| 2025-09-29 | D | 506(b) | $850.0M | $0 | 0.0% | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed.
- N/A OrbiMed Asia GP VI, L.P. — Executive Officer, New York, NY
- N/A OrbiMed Advisors VI Limited — Executive Officer, New York, NY
- Sven H. Borho — Director, New York, NY
- Carl L. Gordon — Director, New York, NY
- W. Carter Neild — Director, New York, NY
- Sunny Sharma — Director, Mumbai, K7
- David G. Wang — Director, Shanghai, F4
Placement agents
- Merrill Lynch, Pierce Fenner & Smith Incorporated · 17 RE raises
- J.p. Morgan Securities Llc · 14 RE raises
- Ubs Financial Services Inc. · 13 RE raises
- Ubs Switzerland Ag · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.